Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418544 | 1.00 | HRH3 (0.51) | HRH3AOC3HRH1MAPTMAPK1 | |
| SCHEMBL1790797 | 0.90 | HRH3 (0.55) | HRH3AOC3HRH1MAPTMAPK1 | |
| SCHEMBL2194239 | 0.89 | HRH3 (0.51) | HRH3AOC3HRH1MAPTMAPK1 | |
| SCHEMBL2188621 | 0.89 | HRH3 (0.51) | HRH3AOC3HRH1MAPTMAPK1 | |
| SCHEMBL2270809 | 0.79 | HRH3 (0.58) | HRH3HRH1MAPTMAPK1KDM2B | |
| SCHEMBL1787581 | 0.77 | HRH3 (0.48) | HRH3HRH1KDM2BCYP2D6 | |
| SCHEMBL2221314 | 0.76 | HRH3 (0.44) | HRH3AOC3HRH1CYP2D6 | |
| SCHEMBL2264778 | 0.76 | HRH3 (0.44) | HRH3AOC3HRH1CYP2D6 | |
| SCHEMBL2264905 | 0.75 | HRH3 (0.49) | HRH3HRH1CYP2D6 | |
| SCHEMBL1790800 | 0.75 | AOC3 (0.43) | HRH3AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | HRH3, HRH4, HRH2 | HRH3 1/4885AOC3 468/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.